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1. Introduction
For most of the 20th century, the human stomach has been considered an environment that
is inhospitable for the growth of any bacteria. But the first isolation of a curved, microaero‐
philic, gram-negative bacterium, H. pylori by Marshall and Warren in 1982 is responsible for
provoking a rupture in contemporary popular medical doctrines, thereby enforcing changes
in global conceptions of gastroduodenal disorders. H. pylori is of growing concern today be‐
cause of its crucial role in the pathogenesis of chronic gastritis, peptic ulcer diseases and in
the multi-step carcinogenic processess of gastric cancer, a fourth most common cancer
worldwide while the second cause of cancer related deaths. Epidemiologically, more than
50% of the world population is infected by this bacterium and develops persistent inflam‐
mation in their stomachs, which lasts for decades unless treated with antibiotics. About
60-95% of peptic ulcer diseases are thought to be idiopathic and H. pylori is one of the causa‐
tive agents of nearly all of these cases in adults. About 15% of infected individuals become
symptomatic for peptic ulcer (duodenal or gastric) as a long-term consequence of infection.
The apparent paradox suggests that the mere presence of H. pylori in the stomach is insuffi‐
cient to cause gastric disease, rather requiring additional conditions. Beside bacterial genet‐
ics, host genetic factors, hygiene, microbiome, medication, food habits along with life-style
might be additional reasons for H. pylori-induced pathogenecity.
Progression of gastric inflammation by long term association of H. pylori  in stomach can
broadly be viewed in two ways. The first being the antigenic stimulation of H. pylori and
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the  second  one  is  the  host  immune  response  to  microbe  that  is  necessary  for  bacterial
clearance yet causing injury to the host. Besides, H. pylori must bear an arsenal of specif‐
ic  virulence  factor  such  as  the  cytotoxin-associated  gene-pathogenicity  island  (cag-PAI),
vacuolating associated cytotoxin gene A (vacA),  outer membrane protein A (oipA), blood
group antigen binding adhesin (babA), lipases and lipopolysaccharides (LPS) be potential‐
ly toxigenic to initiate the process of inflammation in the host gastric tissues. These anti‐
gens  can  interact  with  specific  host  proteins,  initiating  a  cascade  of  signaling  processes
which  ultimately  affect  many  abnormalities  like  loss-of-function  of  tumour  suppressor
genes, gain-of-function of oncogenes, dysregulation of miRNAs and several defects in cy‐
toskeleton and cell-cell junctions.
On the other hand, the host immune response is characterized by the cardinal signs of in‐
flammation. Both innate and adaptive immune systems are activated by inhabiting H. pylori.
The principal mechanism of innate immunity includes complement activation, phagocytosis
and the inflammatory response. The adaptive immune response is guided mainly by T cells
including T regulatory cells (Tregs), T helper (TH1) cells and more recently reported TH17
cells and their corresponding cytokines. H. pylori has evolved with unique features to evade
immune response. It also exhibits multiple strategies to reside within the host yet escaping
host immune response (refer Box 1). Thus, it remains a mystery as to why some infected pa‐
tients are susceptible to disease manifestation compared to others who remain asymptomat‐
ic throughout their lives in spite of infection.
∙ Acidic milieu: Gastric niche is acidic, while H. pylori grow normally at neutral pH but fails to grow at pH below 4. To
overcome this problem, the bacteria secrete urease, which breaks urea into water and ammonia. This property has
been successfully exploited for disease diagnosis known as urea breath test.
∙ Non-Adherence: For successful colonization, the bacterium has to successfully adhere to the gastric wall, but the
peristaltic movements of the stomach provide a hostile barrier. However, H. pylori possess spiral shaped polar flagella,
which permit proficient hydrodynamic movement within gastric mucous. About 20% bacterial population adheres to
gastric epithelial cells but majority remains within mucous layer. H. pylori express several outer membrane proteins
(OMPs) which bind to their receptors on gastric epithelial cells. For example, BabA is an adhesion molecule that binds
to the fucosylated Lewis b receptor, SabA binds to sialyl LewisX receptor and OipA not only adhere onto gastric
epithelial cells but also triggers β-catenin activation and secretion of proinflammatory cytokines.
∙ Host Immune Response: Activation of host immune system results in inflammation. Interestingly, this gram-negative
bacterium has evolved with anergic lipopolysaccharide (LPS) and flagelin due to its modification of lipid a component
that has about 103 times less endotoxin activity in comparison to LPS of other gram-negative bacteria. Moreover, H.
pylori can acquire molecular mimicry by taking cholesterol from its host into its own membrane. Furthermore, Tregs
upregulation following infection may suppress antibacterial immune response.
Box 1. Barriers overcome by H. pylori for colonization and infection in host.
It is known from several studies that MMP, a family of zinc-dependent endopeptidases that
selectively degrade or remodel most of ECM components and other structural molecules are
intimately associated to different diseases including gastric ulcer and cancer. At present,
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both in vivo and in vitro studies have established the activation of several MMPs during H.
pylori association. However, very few studies have been made till date dissecting the signifi‐
cant role of TH cell subsets and MMPs during the progression of H. pylori related gastric in‐
flammation. In this review, we aim at to highlight the influence of TH cells on modulation of
MMPs activity during H. pylori induced gastric inflammation that further open up new ave‐
nues both in research and clinical perspectives in future. Since the present scenario failed to
generate much hope on H. pylori vaccination we will emphasise on how H. pylori behave
within gastric niche and how do they trigger inflammation?
2. Gastric inflammation: An overview
Persistent association of microaerophilic, gram-negative enteric bacteria results in chronic
gastric inflammation which in turn leads to gastric cancer. Accumulating evidences suggest
that H. pylori-induced inflammation is initiated both by host and bacterial factors. In addi‐
tion, environmental factors also play potent role in disease progression. However, the actual
pathogenesis behind chronic inflammation is not well understood. H. pylori enter inside
stomach via fecal-oral route mainly by contaminated food and water (Klein et al., 1991, Hop‐
kins et al., 1993). The most probable mode of transmission is via direct contact with the in‐
fected patient within the family or a common source of contaminated water or food of a
locality (Hopkins et al., 1993) (Nurgalieva et al., 2002).
Gastric inflammation is accompanied by induction of oxidative stress by reactive oxygen
species (ROS), inducible nitric oxide synthase (iNOS) and subsequent secretion of proin‐
flammatory  cytokines  like  interleukin  (IL)-1β,  IL-6  and  tumor  necrosis  factor  (TNF)-α
(Yamaoka et  al.,  1996).  Gastric  epithelial  cells  also secrete  IL-8 (Jung et  al.,  1997)  which
attracts the polymorphonuclear (PMN) cells.  Local inflammation is also associated to re‐
duced prostaglandin synthesis  and increased infiltration of  mast  cells,  neutrophils,  mac‐
rophages  and  H.  pylori  specific  IgA  and  IgG  antibodies  (Warren,  2000).  The  dendritic
cells (DCs), which are present in the epithelial layer, present the antigens with their Toll-
like  receptors  (TLRs)  to  naïve  T  cells  and  thereby  initiate  humoral  immune  response.
Moreover, H. pylori infection stimulates iNOS and other enzymes including myeloperoxi‐
dases,  NADPH oxidases,  eosinophil  peroxidases.  These  enzymes  trigger  ROS and  reac‐
tive  nitrogen  species  (RNS)  production,  which  induce  DNA  damage  (Wang  et  al.,
2005).Therefore,  H. pylori-mediated inflammation is  complex and no single factor can be
targeted  for  successful  clinical  therapy.  For  example  the  study  on  mast  cell-deficient
KitlSl/KitlSl-d  mice  reported that  mast  cells  also  contribute  to  neutrophil  recruitment  and
inflammatory response due to H. pylori  infection thereby contributing a part  though are
not essential for vaccine-induced immunity (Ding et al., 2009).
Over-secretion of pro-inflammatory cytokines and growth factors promote neovascularisa‐
tion, which cause invasion and metastasis. Vascular endothelial growth factor (VEGF), the
main mediator of angiogenesis is reported to be over-expressed in 54% of severe gastric can‐
cer patients with lymph node and liver metastasis (Saukkonen et al., 2003). Along with
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VEGF, other pro-angiogenic factors like IL-6, IL-8 and iNOS are also upregulated in tumor
cells. IL-8 promotes angiogenesis in gastric tumor by interacting with its receptors CXCR1
and CXCR2, present on surface of endothelial cells. Over expression of iNOS has been ob‐
served in both primary tumors as well as lymph node metastases compared to normal mu‐
cosa (Wang et al., 2005). Excess nitric oxide increases the activity of VEGF thereby
promoting blood flow, vascular permeability and endothelial cell proliferation and migra‐
tion (Wang et al., 2005). Other than stimulating angiogenesis, iNOS promotes gastric carci‐
noma through various ways including inhibiting DNA repair enzymes, inducing oxidative
DNA damage, oncogene expression and apoptosis deregulation (Ohshima et al., 2003). The
niche of H. pylori colonization is also a determinant factor for the severity of the disease. For
example; chronic corpus-predominant gastritis leads to mainly gastric adenocarcinoma, in
contrast antrum-predominant gastritis may promote duodenal ulceration. Also patients
with H. pylori infection in the distal part (antrum) of the stomach may develop duodenal ul‐
cer but are somewhat protective from gastric cancer. Thus, duodenal ulcer may have a pro‐
tective role from development of gastric adenocarcinoma (Saukkonen et al., 2003).
In cancer tissues, there is very less information available regarding the association between a
specific factor and methylation of a gene. Aberrant DNA methylation is frequently associated
with different human cancers. DNA methylation is involved with change in gene expression
pattern, which can be confirmed by measuring the mRNA levels of the corresponding genes.
Nakajima et al, in human gastric cancer cell lines showed that DNA methylation pattern due to
H. pylori infection was conserved in the promoter region of 48 genes. Interestingly, this methyl‐
ation pattern remained in gastric cancer patients; who were previously infected with H. pylori
but later eradicated (Nakajima et al., 2009). Similarly from Mongolian gerbils (Niwa et al., 2010)
10 CpG islands showed specific methylation pattern after H. pylori infection, which sustained
the inflammatory response of the host towards H. pylori infection rather than H. pylori itself.
Therefore with reduction of inflammation, there was reduction in DNA methylations, even as
H. pylori load remained unchanged. So, long term H. pylori infection induces chronic inflamma‐
tion, the later maintain epigenetic changes inside host’s genome.
From evolutionary view point, the successful adaptability of H. pylori within the host can be
attributed to their versatile genetic diversity, which has specifically evolved for a habitat,
population or geographical locations. The virulence of H. pylori depends on what specific
antigens they possess. Interestingly, nature selected both Cag A+ (high virulence) as well as
CagA- (less virulent) bacteria during the course of evolution. Possibly, high-virulence im‐
plies successful host attack; while less-virulence implies their innovative masking strategy
from host’s immune response. So, diversity seems to help bacteria to keep the host alive
even with infection, in turn preserving them. Therefore, one of the most intriguing aspects
of H. pylori is its genetic diversity, the biological significance of which is enigmatic (Covacci
and Rappuoli, 1998, Logan and Berg, 1996). The bacteria colonize the gastric mucus layer
and persist livelong in close vicinity with epithelial cells. Though bacterial colonization de‐
pends on their secreting system, which they use as molecular syringes to inject their virulent
component into the host (Kamada et al., 2012), yet competition also play crucial role for H.
pylori colonization inside the gut and hence, the gut microbiota is often referred to as the for‐
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gotten organ (Sperandio, 2012). The human gastrointestinal tract hosts bacterial cells as
many as 10 times more than total number of cells of human body (Hooper and Gordon,
2001). These bacteria compete with pathogens like H. pylori for food source. Therefore,
changes in microenvironments like high salt-intake, change in life-style or food-habits give
stress on normal gut microbiota and helping H. pylori to proliferate and induce infection.
3. Genetics of H. pylori and gastropathy
H. pylori are a highly heterogeneous bacterial species, both genotypically and phenotypical‐
ly, and are highly adapted for survival in the gastric niche. The genomic diversity of H. pylo‐
ri parallels that of its host species, consistent with colonization of the earliest humans and
co-migration out of east Africa at least 60,000 years ago (Censini et al., 1996). H. pylori colo‐
nize the stomach for almost the entire lifetime of the host. H. pylori colonization of the gas‐
tric mucosa typically occurs in early childhood and may persist for decades or for life,
unless eradicated by antimicrobial treatment.
The clinical outcome of H. pylori infection is determined by multiple factors, including host
genetic predisposition (especially certain cytokine polymorphisms (Amieva and El–Omar,
2008), H. pylori strain heterogeneity and environmental factors such as dietary salt intake
(Fox et al., 1999, Beevers et al., 2004, Hwang et al., 1994). H. pylori heterogeneity and the as‐
sociation with H. pylori virulence factors have been intensively investigated over the past
two decades (Covacci et al., 1993, Atherton et al., 1995, Argent et al., 2004). One possible
problem that has complicated the identification of definite disease-specific H. pylori viru‐
lence factors is the considerable geographic diversity in the prevalence of H. pylori virulence
factors. The major H. pylori candidate virulence factors include cagA, vacA, babA and dupA.
cagA was the first reported gene that varies in H. pylori strains and considered as a marker for
the presence of cag-PAI, which include a number of other genes associated with increased viru‐
lence (Broutet et al., 2001). The gene that encodes CagA is part of a ~40 kb horizontally acquired
DNA segment in the H. pylori genome known as cag-PAI (Censini et al., 1996). The cag-PAI also
contain genes encoding a type IV secretion system, to ensure efficient translocation of the Ca‐
gA protein into the host epithelium.The CagA also disrupts the tight junctions and causes loss
of apical-basolateral polarity in epithelial cells (Amieva et al., 2003).
The extent of biological activity of CagA is directly associated with the number of phosphoryla‐
tion sites or the number of EPIYA motifs present at the C-terminal region of CagA (Higashi et
al., 2002b, Azuma, 2004, Azuma et al., 2004). Thus, molecular weight of the CagA protein varies
from 128 kDa -148 kDa and the cagA gene shows extensive length polymorphism at the 3’ end.
Several attempts were made to type the distinct CagA proteins and the cagA genes on the basis
of its length polymorphism at the C-terminal and 3' ends, respectively (Argent et al., 2005,
Dong et al., 2002, Owen et al., 2003). Mutational analyses revealed that the first two EPIYA mo‐
tifs (Y1 and Y2 positions) have little, if any, biological function while the other motifs are re‐
sponsible for the CagA phosphorylation and CagA-SHP-2 complex formation (Higashi et al.,
2002a). Moreover, the amino acid sequences, which are repeated among the third, fourth and
Unveiling the Intricacies of Helicobacter pylori-Induced Gastric Inflammation: T Helper Cells and ...
http://dx.doi.org/10.5772/54193
117
fifth EPIYA motifs differ among strains isolated from west and east Asia. Accordingly, CagA
was typed as Western-CagA-specific sequences (WSS) and East Asian-CagA-specific sequen‐
ces (ESS) and this difference may account for differences in disease outcome between the two
geographical regions. Recent study suggested that EPIYA motifs as well as the spacer sequence
units were present as distinct insertions and deletions, which possibly have arisen from exten‐
sive recombination events (Chattopadhyay et al., 2012). Moreover, several new CagA types
have been identified, a new typing system has been proposed. It is hypothesized that a cagA
gene encoding higher number EPIYA motifs may perhaps have arisen from cagA genes that en‐
code lesser EPIYA motifs by acquisition of DNA segments through recombination events ( refer
figure 1a). Chattopadhyay et al also described that carrying a particular type of CagA is not the
only determinant for the disease outcome especially in the developing countries like India,
where multiple infections with different CagA primary structures are possible. Recent study
regarding the multiple infections and microdiversity among the colonies from individual pa‐
tient in Indian population suggested that most of the patients have acquired H. pylori due to re‐
peated exposure to this pathogen with different genetic make-up, which may increase the
possibility of super infections(Patra et al., 2012). Genetic exchanges between these unrelated H.
pylori strains may support certain H. pylori variant to grow better in a given host than the paren‐
tal strain and thereby increasing the possibility for the severity of the infection (Patra et al.,
2012) (refer figure 1). Additional isolates of the sequenced H. pylori strain J99 from its human
source patient after a 6-year interval was analyzed in another study (Israel et al., 2001). Patterns
of genetic diversity were distinct among the additional J99 isolates, both when compared with
each other and to the original prototype isolate. Their results indicated that within an apparent‐
ly homogeneous population remarkable genetic differences existed among single-colony iso‐
lates of H. pylori. Direct evidence that H. pylori has the capacity to lose and possibly acquire
exogenous DNA is consistent with a model of continuous microevolution within its cognate
host (Israel et al., 2001).
Soon after H. pylori’s discovery, it was reported that a protein in H. pylori broth culture fil‐
trates could cause the formation of large intracellular vacuoles in cultured mammalian cells
(Leunk et al., 1988). The H. pylori protein responsible for this effect (designated VacA) is en‐
coded by a chromosomal gene known as vacA. The vacA gene encodes a precursor protein of
140 kDa (Cover et al., 1994, Telford et al., 1994, Lupetti et al., 1996). Proteolytic processing of
the protoxin during secretion yields the mature toxin (∼90 kDa). Secreted VacA can be fur‐
ther processed into an N-terminal fragment of 33 kDa (p33) and a C-terminal fragment of 55
kDa (p55), but cleavage does not seem to be necessary for VacA activity. Although the p33
domain exhibits pore-forming activity necessary for vacuole formation (McClain and Cover,
2003), and the p55 domain is responsible for target cell binding (Reyrat et al., 1999), Several
families of vacA alleles can be distinguished on the basis of diversity near the 5′ terminus of
vacA (which is known as the s-region s1a-c and s2), the intermediate region (i1, i2) and in the
mid-region of the gene (known as the m-region m1, m2) (Atherton et al., 1995, Rhead et al.,
2007). Most strains with s1/m1 genotype and some of the s1/m2 express the cytotoxin while
strains with s2/m2 genotype do not express a toxic VacA (Cover and Blanke, 2005). Studies
have shown that VacA contributes to H. pylori colonization, persistence and disease outcome
in vivo. H. pylori strains that contain vacA alleles of the s1 type are associated with an in‐
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creased risk for development of peptic ulcer disease and gastric cancer compared with
strains containing vacA alleles of the s2 type (Atherton et al., 1995, Van Doorn et al., 1999,
van Doorn et al., 1998, Figueiredo et al., 2002). However, east Asian strains are almost uni‐
versally s1/m1 and are not associated with any specific clinical outcome (Ito et al., 1997, Ito
et al., 1998).
Figure 1. Schematic representation of generation of genetic diversity in cagA gene involving EPIYA motifs (Ys):
(a) genetic diversity arise within a cagA gene from another cagA gene that encode lesser EPIYA motifs by acquisition
of DNA segments through homologous recombination events or (b) genetic variation within a cagA gene may also
result from crossing over within any particular EPIYA motif (for example Y3 as shown in the figure). In all the events,
crossing over can also happen involving DNA strands I and IV, as mentioned above and therefore can generate more
genetic variation within cagA gene. It is to be noted that DNA 1 and 2 are genetically different. The rationale behind
making the two strands of a DNA dissimilar due to acquision of new mutations is highlighted.
Approximately 4% of the H. pylori genome encodes a diverse repertoire of outer membrane
proteins (OMPs), the largest of which is the 21-gene Hop family. Several of the Hop proteins
have been identified as adhesins, the best studied of which is BabA (Ilver et al., 1998, Guruge et
al., 1998). It is an adherence factor expressed in a subgroup of H. pylori strains and binds to difu‐
cosylated Lewis b (Leb) blood group antigens found on gastric epithelial cells. The babA gene
was cloned initially from strain CCUG17875, which contains a silent babA1 gene and an ex‐
pressed babA2 gene. The sequence of these two genes differs only by presence of a 10bp dele‐
tion in the signal peptide sequence of babA1 that eliminates its translational initiation codon
(Prinz et al., 2001). Initial studies indicated that H. pylori babA2+ strains are associated with an
increased risk of peptic ulcers and distal gastric adenocarcinoma, whereas babA2− strains are
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more often associated with uncomplicated forms of gastritis (Gerhard et al., 1999, Prinz et al.,
2001). babA2-genopositive H. pylori usually coexists with other disease-related H. pylori viru‐
lence-factor genes, such as vacA s1 and cagA. Tripositive strains, which have cagA+, vacA s1, ba‐
bA2+in a single H. pylori species, further increase the risk of developing gastroduodenal ulcers
and distal gastric cancer(Prinz et al., 2001, Gerhard et al., 1999).
Recent studies have proposed the possibility of using genetic markers in the plasticity zone
as indicators of pathogenicity for H. pylori infection, in spite of a lack of credible knowledge
regarding the functions of the putatively encoded proteins in this cluster. It seems that these
determinants may play a key role in determining the virulence capacity of H. pylori strains
either directly or by encoding factors that may lead to varying clinical outcomes. The associ‐
ation between some of the ORFs in the plasticity zone and various disease categories has
been previously reported. For instance, Occhialini et al. (Occhialini et al., 2000) found that
two single ORFs (jhp0940 and jhp0947) were more prevalent in strains isolated from patients
with gastric adenocarcinoma in Costa Rica. However, Santos et al. (2003) (Santos et al., 2003)
showed the association between jhp0947 and duodenal ulcer (DU) as well as gastric cancer
in Brazilian patients. This was once more confirmed for jhp0947 and jhp0949 genes in DU pa‐
tients from the Netherlands (de Jonge et al., 2004).
Recently, a novel duodenal ulcer promoting gene (dupA) was described, which consists of
two ORFs jhp0917 and jhp0918 and form one continuous gene by the insertion of a base T or
C after the position 1385 of the jhp0917 in the 3' region (Lu et al., 2005). This gene (homo‐
logues to virB4) is located in the plasticity region and is associated with increased risk of DU
and protective against gastric atrophy, intestinal metaplasia and gastric carcinoma in Japan
and Korea (Lu et al., 2005). However, the role of dupA as a virulence marker is still contro‐
versial. Some researchers have supported the interpretations of Lu et al. (2005) (Lu et al.,
2005) but others did not find any association. Hussein et al. (2008) (Hussein et al., 2008) have
reported that dupA gene is associated with peptic ulcer but they did not find any negative
association with gastric cancer in Iraqi population. In Chinese and north Indian populations
significant association of dupA with DU was established (Arachchi et al., 2007). In contrast,
Argent et al. (2007)(Argent et al., 2007) showed no association of dupA gene with DU in pop‐
ulation from Belgium, South Africa, China and the United States. Meta-analysis based study
by Shiota et al. (2010) (Shiota et al., 2010) has shown that the presence of dupA gene was sig‐
nificantly associated with DU. Another systematic review confirmed that dupA was associat‐
ed with gastro duodenal diseases (Hussein, 2010). Study in southeast Indian population
demonstrated that dupA gene was 6.5 times more prevalent in duodenal ulcer patients than
non-ulcer patients (Alam et al., 2012). Infection with the dupA-positive H. pylori increased
the risk for DU overall and this evidence was significant in Indian study (Alam et al., 2012).
The discrepancy of dupA association with diseases outcome could be related to the limita‐
tion of PCR techniques for detecting the intact dupA gene or may be a consequence of the
genetic diversity of H. pylori, which is at a level as yet unseen among other bacterial patho‐
gens (Covacci and Rappuoli, 1998, Logan and Berg, 1996, Blaser 1998).
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4. Immunobiology of host and H. pylori interaction in both in vivo and in
vitro
Through evolution, H. pylori have gradually developed highly sophisticated adaptation for
successful colonization and better adaptation inside the host’s microenvironment. Interest‐
ingly, humans too show some tricky adaptation to check H. pylori colonization inside the
stomach. The in vitro studies documented (Linden et al., 2009) that human gastric cell-sur‐
face mucin MUC1, a large glycoprotein, prevents the adhesion of the bacterium with the epi‐
thelial layer. H. pylori usually bind to MUC1 through their cell surface receptor BabA and
SabA adhesion proteins, but the human gastric cells shed these MUC1 glycoproteins by
MUC1 sheddases ADAM17 and MMP-14. Similarly, in murine model too, MUC1 prevents
H. pylori colonization (McGuckin et al., 2007).
After entering the gastric milieu, most of the bacteria remain in the gastric mucosa and only
about 10% H. pylori bind with the gastric epithelial cells (Oh et al., 2005, Semino-Mora et al.,
2003). So it becomes difficult to eradicate the bacteria with antibiotics. H. pylori adhere via Ba‐
bA (Ilver et al., 1998) with histo-blood group antigen Leb expressed over gastric epithelial cell
surface. The other protein that significantly contribute stable adherence of H. pylori is sialic
acid-binding adhesion protein (SabA) which bind to LewisX (Mahdavi et al., 2002), a glyco‐
sphingolipid that is significantly expressed during gastric dysplasia (Hansson et al., 1993).
The genetic study in relation to the virulence factor has been extensively studied in relation
to cagA and vacA (Peek and Crabtree, 2006). CagA positive H. pylori strains impart higher
risk for gastric cancer (GC) than infection of strains that devoid of cagPAI (Parsonnet et al.,
1997, Enroth et al., 2000). After stable adherence, H. pylori with its type IV secreting system
translocate CagA into the gastric epithelial cells (Segal et al., 1999). Once inside, Cag A is
differentiately phosphorylated at its specific tyrosine residues in their EPIYA (Glu-Pro-Ile-
Tyr-Ala) motifs located at the C-terminal region of the protein (Higashi et al., 2002a). This
phosphorylation is carried out by host’s Src and Abl family kinases (Selbach et al., 2002,
Poppe et al., 2007). A variety of tyrosine phosphorylation motifs results in difference in viru‐
lence and consequently host infection(Higashi et al., 2002a).This overall difference in phos‐
phorylation of the tyrosine motifs may be the reason for diversity of GC incidence in the
global scenario (refer figure 1). Phosphorylated CagA can interact with several other host
proteins and ultimately targets specific proteins including oncoprotein, tumor suppressing
protein, junction proteins, cell cycle regulators and several other transcription factors. These
collectively affect the cell’s normal physiology and propel the cells toward carcinoma. The
phosphorylated CagA protein binds to SH2 domain of tyrosine phosphatase and increases
its phosphatase activity (Higashi et al., 2002b, Hatakeyama, 2004). SHP-2 is an important
component involved in intracellular signaling during development and haematopoiesis
whose gain-of-function lead to lymphoid and myeloid malignancy (Tartaglia and Gelb,
2005). Due to the intrinsic membrane tethering property of CagA the CagA-SHP-2 complex
localizes to the plasma membrane of the host epithelium (Higashi et al., 2002b), leading to
deregulation of the SHP-2. This event is necessary and sufficient to change the gastric epi‐
thelium to a transformed epithelium, which is characterized by altered cellular proliferation,
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migration and elongated cell morphology known as hummingbird phenotype (Higashi et
al., 2002b, Yamazaki et al., 2003). So, transgenic expression of CagA also manifest gastroin‐
testinal as well as hematopoietic abnormalities (Ohnishi et al., 2008). H. pylori having a func‐
tional cag PAI also stimulate cultured gastric epithelial cells to secrete the pro-inflammatory
cytokine or chemokine IL-8 (Crabtree et al., 1995). CagA binds to SHP-2 and induces ‘hum‐
ming bird phenotype’ in AGS cell line involving extracellular signal-regulated kinase (Erk),
mitogen-activated protein (MAP) kinase pathway and dephosphorylating focal adhesion
kinase (FAK) (Tartaglia and Gelb, 2005) (Higashi et al., 2004). Cag A also interacts with Crk
and thereby promotes loss of adhesion in gastric epithelial cells (Suzuki et al., 2005). In addi‐
tion, Cag A also interacts with other factors including c-Met and Grb2 (Churin et al., 2003,
Mimuro et al., 2002). In addition to the above components, H. pylori also secrete nucleotide-
binding oligomerization domain-1 (NOD1), a specific peptidoglycan of gram-negative bacte‐
ria (Viala et al., 2004), a potent molecule involved in stimulating the host innate immune
response (Fox and Wang, 2007).
The other virulence factor in H. pylori is VacA. The intra-luminal environment of VacA-in‐
duced vacuoles is acidic, and the vacuoles are endocytically active (Cover et al., 1991, Papini
et al., 1994). A current model to explain the mechanism by which VacA induces vacuole for‐
mation proposes that VacA binds to the plasma membrane of cells, is internalized by cells,
forms anion-selective channels in endosomal membranes and alters the permeability of
these compartments. Within 10 minutes of addition of VacA to a human gastric adenocarci‐
noma cell line (AZ-521), two classes of mitogen-activated protein kinases (p38 and ERK1/2)
and the activating transcription factor 2 (ATF2) signalling pathway are activated (Nakayama
et al., 2004). Within 30–60 minutes of the binding of VacA to BHK-21 cells expressing recep‐
tor protein tyrosine phosphatase β (RPTPβ, also known as Ptprz), tyrosine phosphorylation
of G-protein-coupled receptor kinase interactor (Git1) can be detected (Fujikawa et al., 2003).
In another model system, binding of of VacA to a mast cell line (RBL-2H3) cells results in a
rapid change in cytosolic calcium concentrations (de Bernard et al., 2005). VacA is also re‐
ported to induce pro-inflammatory effects. It stimulates the production of TNF-α and IL-6
by mast cells and induces chemotaxis and degranulation of these cells (de Bernard et al.,
2005). Moreover, VacA treatment stimulates expression of cyclooxygenase-2, a proinflam‐
matory enzyme, in neutrophils and macrophages (Boncristiano et al., 2003). Thus, the effects
of VacA on immune cells are complex and are characterized by both immnostimulatory and
immnosuppressive actions.
5. Role of T cells in H. pylori infection
Very limited information is available on how the host immune system; particularly the
adaptive immune system is modulated by H. pylori infection to promote gastric diseases.
Chronic inflammation associated to H. pylori infection is known to promote gastric cancer in
some individuals (Suerbaum and Michetti, 2002, El-Serag and Rudolph, 2007). In contrast to
earlier notion that T cells generate antitumor responses, as supported by the fact that Rag-/-
mice and mice with mutated interferon signaling promote more tumor development, recent
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advances establish new insights into T cells particularly TH17 response in aggravating gas‐
tric cancer due to H. pylori colonization (Erdman et al., 2003, Dunn et al., 2006).
Bacterial chemotaxis is their inherent property by which it can migrate from a harsh envi‐
ronment towards more favorable environment. Genetically modified H. pylori (Che-) cannot
respond to environmental stimulus although they retain power of locomotion. In animal
models, they manifest marginal colonization abnormalities and relatively less inflammation
severity. Interestingly, Che- H. pylori fail to colonize epithelial cells and gastric glands vigo‐
rously. This support the fact that chemotaxis helps the bacteria to successfully cross the thick
mucus layer with their unipolar flagella and adhere to gastric epithelial cells which are resi‐
dent of antigen presenting cells (APCs); thus promoting antigen presentation to naïve T cells
(Rolig et al., 2011). In the process, epithelial cells also secrete chemokines for recruiting
APCs like DCs. DCs with their Toll-like receptors recognize specific antigens of the bacteria;
and in turn presents those antigenic peptide fragments to T cells to promote class switching
and differentiation in TH1 subsets, T regs or more recently classified TH17 cells (refer figure
2). Specific cytokines secreted by these cells regulate host immune response leading towards
chronic inflammation.
Figure 2. Maturation of DC and formation of T cell subsets following exogeneous stimuli: Maturation of dendrit‐
ic cell (DC) occurs under the influence of different pathogen-associated molecular patterns and specific host cyto‐
kines.Various physiological and environmental factors also trigger DC for successful antigen presentation. Upon
maturation, DC expresses MHC II and co-stimulatory molecules including cytokines and growth factors which enhance
antigen presentation, naïve T cells activation followed by differentiation into TH1, TH2, TH17 and regulatory T cell
(Treg). Each T cell subtypes has its own signature cytokines which perform effector functions as well as maintain bal‐
ance among various other T cell subtypes.
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The mechanism underlying differentiation of T cell has been intensively investigated: Stat1
and Stat4 signaling drive TH1 response; Stat6 signaling promotes TH2 whereas Stat3 signal‐
ing drives TH17 responses. IL-2 drives TH1 responses and results in (interferon) IFNγ pro‐
duction; that may have carcinogenic effect. However, role of TH2 and TH17 are not well
known (Dunn et al., 2006) until recent reports suggest that TH17 may play a pivotal role in
H. pylori-mediated gastric cancer (Rolig et al., 2011). In addition, nuclear transcription fac‐
tors, NF-κB are normally activated during H. pylori infection. This is not unusual since con‐
ditional knock-out mice have shown that NF-κB not only signals epithelial cells to undergo
transformation but also myeloid cells which are source of inflammation (Greten et al., 2004,
Karin and Greten, 2005). NF-κB in turn promotes IL-6 expression and contribute to carcino‐
genesis (Naugler and Karin, 2008). Key features that appear to be IL-6 specific are triggering
proliferative, pro-angiogenic and anti-apoptotic genes including Stat3 (Yu and Jove, 2004).
Under Stat3 signaling, the role of TH17 in case of an enteric bacteria like H. pylori become
significant. Recent studies have focused on the post-transcriptional modification within na‐
ive T cells that are ultimately primed by APCs for proliferation and differentiation into ef‐
fecter T cell subtypes. Posttranscriptional regulation rather repressions of target genes may
be responsible for development of T cell subtypes. On this account miRNA has received
much attention in various diseases including cancer. miR-155 is expressed in variety of im‐
mune cell type’s namely DCs, macrophages, TH1 and TH17 cells. In myeloid cells, miR-155
is induced by TLR and TNFα that in turn activate AP-1 and NF-κB transcription factors
(Oertli et al., 2011). miR-155-/- mice show TH2 bias development, signifying miR-155 mediat‐
ed TH1 response. miRNA is also reported to be involved in TH17 differentiation (O'Connell
et al., 2010). It was demonstrated that miR-155-/- mice were incapable of spontaneously ar‐
resting H. pylori load, lacked vaccine-induced protective immunity and failed to induce in‐
fection-associated preneoplastic pathology (Oertli et al., 2011).
The role of Tregs in modulating host immune response during H. pylori infection has been
speculated for quite a sometime. Tregs are a subset of T cells that suppresses the host im‐
mune response and are associated with cancer and parasite infection. These specialized T
cells express markers like CD4, CD25, and FoxP3. Tregs increase the tolerance towards self-
antigens and at the same time facilitates the growth of tumors through immunosupression.
Once differentiated Tregs proliferate and maintain their population through autocrine sig‐
naling pathway and starts secreting immunosuppressive cytokines like IL-10 and TGFβ (Joe‐
tham et al., 2007). Reports indicate that reduction of Tregs can actually stimulate the
immune response against other microbial infections (Belkaid et al., 2002). In recent years, the
observation shows that the rate of Treg infiltration in human stomach is proportionate to the
degree of inflammation and H. pylori density. Interestingly, this study also concluded that
Treg infiltration parallels the increased expression of programmed cell death 1(PD-1), a neg‐
ative regulatory molecule belonging to CD28/B7 family (Wu et al., 2001).
It has been hypothesized that better hygiene in Europe and America has inversely proportional
with the rise of asthma, due to lack of early exposure to microbial antigens. Arnold et al report‐
ed that prior infection with H. pylori in neonatal mice increases the number of long lived Treg
cells in the airways and thereby checks the development of asthma. In support, the experi‐
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ments were performed to sensitized mice with ovalbumin to generate primary T cell response,
following feeding virulent H. pylori to both neonatal and adult mice prior to application of aer‐
osolized allergic antigens. This showed H. pylori infected neonatal mice have reduced airway
hypersensitivity and less number of immune cells in bronchoalveolar lavage in compared to
the control; even to adult mice infected with H. pylori (Papatriantafyllou, 2011).
H. pylori induced gastric inflammation relates to both TH1 and TH2 mediated phenomena.
H. pylori infection was looked out as predominantly TH1 mediated inflammatory pathway.
But recent reports show deviation from the earlier notion. Kido et al (2010) demonstrated
that in humans, an epithelial derived cytokine, thymic stromal lymphopoitein (TSLP), indu‐
ces DC-mediated TH2 inflammatory response and thereby triggering B cell activation in H.
pylori-induced gastritis. H. pylori infection results in mixed T cell response. Several studies
established the upregulation of TH1 (Bimczok et al., 2011), TH2 (Kido et al., 2010), Treg
(Mitchell et al., 2012), TH17 (Shi et al., 2010) subtypes suggesting seems a host immunomo‐
dulatory balance for inflammation. TH17 followed by TH1 (Shi et al., 2010) upregulation
may promote acute inflammation via IL-17 and gelatinase activity (refer figure 3). The above
inflammatory condition is counter balanced by Treg’s IL-10 to promote chronic infection by
partial immunosuppression. Thus, TH17 plays a significant role to develop inflammation
due to H. pylori infection, though better understanding of how TH17 is activated during post
infection along with its exact role during infection remains open for further investigation.
However, post infection when inflammation begin the order of T cell subset activation may
be first through TH17, TH1 lymphocytes (Shi et al., 2010) and finely counterbalanced by im‐
munosuppressive Treg activation. Thus, the frequency of tumor-infiltrated Th17 cells de‐
creases in advanced disease human patients. In contrast, tumor-infiltrated Treg increases
compared with early disease human patients. Therefore, maintenance of fine tune balance
between Treg and TH17 seems crucial (Kao et al., 2010, Maruyama et al., 2010).
6. Tracking the matrix metalloproteinases during infection
Proteinase are a class of enzymes capable of hydrolysing peptide bonds. These biocatalysts
are largely classified into two major groups: exopeptidases and endopeptidases, depending
on the site of cleaving a peptide bond either proximal or distal to the amino or carboxy ter‐
mini of the substrate respectively. They are further subdivided into serine proteases, threo‐
nine proteases, cysteine proteases, aspartate proteases, metalloproteases, glutamic acid
proteases based on their catalytic properties (Hartley, 1960). Source of proteases are mainly
restricted to stomach, pancreas and small intestine; where they are utilized for digestion of
protein. Matrix metalloproteinases (MMPs) are Zn-requiring endopeptidases, the essential
player for ECM remodeling of tissues. The function of MMPs are tightly regulated at several
levels by via different mechanisms including synthesis in zymogen, localization in cellular
compartments like granules or lysosomes, inhibition by protease inhibitors and inactivation
in response to change in pH and/or temperature. However, virulent bacteria colonizing the
gut sometime secrete proteases that can directly activate host MMPs, thereby increasing
their biochemical efficiency to degrade host’s ECM (Löwer et al., 2008). Therefore, disba‐
Unveiling the Intricacies of Helicobacter pylori-Induced Gastric Inflammation: T Helper Cells and ...
http://dx.doi.org/10.5772/54193
125
lance of proteases and/or protease inhibitors play decisive role in chronic inflammation and
cancer (Wex et al., 2004). In this chapter we will limit our discussion to MMPs as their role in
gastric inflammation as well as in gastric cancer is just relevant (Knapinska and Fields).
MMPs comprise more than 29 different proteases that differ in the expression profile, sub‐
strate specificity, subcellular localisation and functional implications (Birkedal-Hansen et al.,
1993). Among them, gelatinases, (MMP-2 and MMP-9) and stromelysin-1 (MMP-3) collec‐
tively cleave gelatins (types I and V), collagens (type IV, V, VII, IX and X), elastin, fibronec‐
tin, laminin and proteoglycan core proteins. The activities of MMPs are regulated by the
endogenous tissue inhibitors of metalloproteinases (TIMPs), while cytokines, growth fac‐
tors, tumour promoters and transcription factors including nuclear factor NF-κB and activa‐
tor protein AP-1 modulate their gene expressions. The balance between MMPs and TIMPs is
a critical factor for diverse cellular functions including cellular proliferation, migration, ad‐
hesion and apoptosis (Somerville et al., 2003). Based on the important role of certain mem‐
bers of MMPs in cancer, including gastric cancer, they have been studied to a large extent in
chronic gastritis and premalignant lesions in the stomach (Pender and MacDonald, 2004,
Schuppan and Hahn, 2000).
To explore the role of host proteinases during H. pylori infection, in vivo models are essential.
Although, a majority of H. pylori strains do not colonize mouse, the few that do have sub‐
stantially contributed in understanding the pathogenic mechanism of this bacterium and
helped largely in the development of therapeutic strategies against it (Kundu et al., 2011).
Because of the ease with which gelatinases MMP-2 and -9 can be assayed in a zymography,
host MMP-9 and MMP-2 activities were reported to be first up regulated in H. pylori infected
gastric mucosa (Kundu et al., 2006, Mori et al., 2003, Kubben et al., 2007). However, reports
regarding the expression of TIMP-1 and TIMP-2 in course of H. pylori infection are not
straightforward. Several studies have reported unchanged or even increased expression of
both TIMP-1 and TIMP-2 (Cheng et al. 2012) while a few others claimed decreased expres‐
sion of TIMP-1 in course of H. pylori infection and augmentation of TIMP-1 expression fol‐
lowing a course of H. pylori eradication therapy (Kundu et al., 2006, Kundu et al., 2011).
Reports of other studies soon followed and workers identified several other MMPs includ‐
ing MMP-3, MMP-7, MMP-1, MMP-13 and MT1- MMP as target genes in H. pylori infection
(Schuppan and Hahn, 2000). While ascribing functionality to these enzymes, localization of
MMP-9 expression was observed in the macrophages infiltrating the gastric mucosa that eli‐
cited the inflammatory response in the host through activation of cytokine networks (Kundu
et al., 2011). A correlation was observed between the expression of MMP-7 and bacterial vir‐
ulence factor CagA and functionally the MMP-7 upregulation was shown to be involved in
the degradation of insulin-like growth factor binding protein-5, leading to higher insulin-
like growth factor-II levels that explained epithelial hyper proliferation and stromal expan‐
sion in H. pylori-infected subjects (Steele et al., 2007). An increasing pool of evidence
suggested the increased expressions of several pro-inflammatory cytokines and in H. pylori-
associated gastro duodenal disorders. Among them, TNF-α and IL-1β are essentially in‐
volved in the activation of NF-κB in gastric epithelial cells (Münzenmaier et al., 1997), which
in turn induces several inflammatory genes including IL-8, iNOS and several MMPs (Wro‐
blewski et al., 2003). Reports suggested that IL-1β was a key mediator for the induction of
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MMP- 1 and -3 in gastric adenocarcinoma (AGS) cells (Wallasch et al., 2002), whereas
MMP-9 induction was regulated via the NF-κB pathway(Kundu et al., 2011). Using the
ADAM-17 deficient mice, it was shown that this protease is essential for the H.pylori-de‐
pendent activation of epithelial growth factor receptor (EGFR) and downstream pathways
including ERK 1/2 and MMP-7 production(Lee et al., 2003). In addition to the epigenetic
dysregulation of MMPs in H. pylori infection, several gene polymorphisms in MMP-1, 3, 7
and 9 have been identified to be associated with ulcer disease or gastric cancer (Matsumura
et al., 2005, Zhang et al., 2004, Alakus et al., 2010, Dey et al., 2012).
Another way of exploring host-pathogen interaction is to co-culture the parasite and the
host cell that it infects. In this regard AGS cell lines co-cultured with H. pylori provide a
good model to intensely investigate the function of bacterial as well as host secreted MMPs.
The functions of bacterial MMPs are currently the focus of investigation. A typical H. pylori
bacterium has around 1500-1600 genes in its genome, out of which at least 20 are proteases.
Notably, a 200 KD zinc-dependent endopeptidase was isolated from H. pylori and found to
be localized on the bacterial outer membrane and like other MMPs it was also secreted into
the conditioned medium. H. pylori also co-cultured with AGS cells also expressed MMP-3
like enzyme and TIMP-3 like protein. Moreover, expression of bacterial MMPs and TIMPs
suggested the involvement of bacterial type IV secretory system which might transfer Cag A
protein into gastric epithelial cells allowing H. pylori to modulate host MMP and TIMP mo‐
bilization which could trigger the onset of H. pylori mediated insult in the host (Windle and
Kelleher, 1997, Göõz et al., 2001, Sokolova et al., 2012, Oliveira et al., 2006).
7. Th-17 governs matrix metalloproteases: A pertinent query in clinical
therapy
Upon H. pylori infection different T cell subtypes in the host having specific surface marker,
cytokine profile and transcription factor, arise from CD4+ T cells (Reiner, 2007).The path‐
ways involved in tissue damage during gastritis or gastric adenocarcinoma are complex.
However, disruption of tissue architecture is deeply associated with a class of proteases
namely MMPs. MMPs are capable of cleaving almost all ECM proteins and connective tis‐
sues (Nagase and Woessner, 1999). It has been observed earlier that H. pylori-induced gastric
ulcer and gastrointestinal diseases are associated with regulation in MMP expression profile
and activity profile involved in gastric tissue (Saarialho-Kere et al., 1996, Pender and Mac‐
Donald, 2004, Hellmig et al., 2006). The major source of MMP in stomach is gastric epithelial
cells (Pillinger et al., 2005, Mori et al., 2003). Several studies were mainly focused on report‐
ing the basic changes occurring on MMPs during infection and the cell signaling cascade as‐
sociated with it. At the same time, significant reports were published from the
immunological perspective upon H. pylori infection on the host. However, the story may not
complete if we don’t connect the two ends of the stick. On a broader view, there are accumu‐
lating evidences that T cell secreted cytokines primarily regulate MMP secretion from the
gastric epithelial cells (MacDonald et al., 1999),though in vitro studies support H. pylori can
alone stimulate gastric epithelial cell lines to secrete MMPs (Crawford et al., 2003, Bebb et
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al.), which are collectively responsible for disrupting tissue architecture. The general view is
that once H. pylori antigen is taken up and presented by antigen presenting cells (APCs) to
naïve T cell, the later start to differentiate into specific effecter T cell subsets. These special‐
ized subtypes of T cells start secreting specific cytokines, which ultimately activate gastric
epithelial cells to produce specific MMPs.
Figure 3. Schematic view of Helicobacter pylori infection and MMPs induction involving both cellular and hu‐
moral components. Cellular response: During infection H. pylori injects CagA with their type IV Secretion System
(TSSIV) into the gastric epithelial cells. CagA phosphorylation occurs by host’s Src/Abl kinases and phosphorylated Ca‐
gA activates a series of signaling molecules including inflammatory cytokines, ROS, MMPs leading to aberrant cellular
function. Humoral response: H. pylori prime the host immune system by various lymphocyte subsets through dendrit‐
ic cells (DC)-mediated antigen presentation to naïve T cell. Under the influence of specific cytokines and foreign anti‐
gens the naïve T cells start class switching and differentiate into effector T subtypes via signature transcription factors.
TH17 and TH1 promote while Treg arrests inflammatory response by secreting immunosuppressive cytokines; thereby
maintaining H. pylori load inside gastric mucosa. TH17 stimulates MMPs through IL-17 and IL-21.
Studies using in vitro system document that H. pylori infection can induce apoptosis and
stimulate release of chemokines from the infected gastric epithelial cells (Cover et al., 2003,
Yamaoka et al., 1998, Bhattacharyya et al., 2002). Interestingly, H. pylori infection in lympho‐
cyte deficient mice fails to develop gastric inflammation. However, administration of T cells
into these animals induces severe gastric ulcer, suggesting T cell mediated inflammatory re‐
sponse play the dominant role in H. pylori-mediated mucosal damage (Eaton et al., 1999, Ea‐
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ton et al., 2001, Smythies et al., 2000). H. pylori infection has a strong Th1 response which is
mediated by Th1 cytokines including IFN-γ, IL-12, and TNF-α (Ernst and Gold, 2000,
D'Elios et al., 1997, Crabtree, 1998, Monteleone et al., 1999, Pender et al., 1997).
Activated CD4+ T cells secrete IL-21, which regulates the growth and functional properties of T
cells, B cells, NK cells and DC (Leonard and Spolski, 2005). Of late, it is reported that IL-21 se‐
cretes from TH17 in Stat-3 dependent manner and in turn IL-21 can induce IL-17 production
the maintaining TH17 cell population in an autocrine manner(Wei et al., 2007). In contrast,
IL-21 is also reported as a TH2 secreted cytokine which prevents the differentiation of naive
CD4+ T cells into TH1 cells (Wurster et al., 2002). Therefore the role of IL-21 though appears
complex, yet it’s a crucial cytokine which promotes gelatinase activities during H. pylori infec‐
tion (Caruso et al., 2007). The other studies by Shi et al demonstrated that IL-17 stimulates
MMP activity (Shi et al., 2010). Thus, TH17 acting as an initiator of inflammation and MMPs
which inturn carry out the effecter function of inflammation. Though, it is yet to be understood
on the backdrop of H. pylori infection but from the above documents a strong correlation of
IL-17 and MMPs is plausible and the TH17-MMP pathway may evolve as one of the crucial one
during H. pylori-mediated gastric inflammation (refer figure 3).
8. Management of H. pylori infection and future avenues
As, much greater percentage of the world’s population are infected with H. pylori compared
to the actual number of people developing symptoms so, it may be plausible that host’s in‐
flammation due to food habits, hygiene and lifestyle contribute to bacterial susceptibility. In
view of this, host’s prior inflammatory history may be a dominant issue over virulence of H.
pylori in the development of gastric diseases. H. pylori are known to induce atrophic gastritis
and achlorhydria. The later is associated with loss of parietal cells which leads to reduced
gastric acid secretion (Fox and Wang, 2007). The rise of intragastric pH above 4.0 accelerates
the growth of a range of bacterial species in gastric juice including H. felis (Williams and
McColl, 2006). In addition to the finding of Cai X et al., that H. felis-infected wild type mice
developed antral gastric cancer, after prolonged achlorhydria along with undetectable H. py‐
lori; Ekstroma et al reported the difficulty in detecting H. pylori from patients with severe
achlorhydria (Ekstrom et al., 2001) (Cai et al., 2005), even though achlorhydric mice develop
pathophysical manifestation like gastrin-deficient ones. (Zavros et al., 2005, Zavros et al.,
2002).Therefore, H. pylori-induced atrophic gastritis and achlorhydria, though progression to
severe gastric diseases may be partly contributed by other bacteria including H. felis, remain
open for further investigation.
The study on tribal populations in India reported that biopsy samples contain strains having
cag PAI and putatively toxigenic s1 alleles of vacA, which contribute to virulence when ac‐
tive, and this is in accord with the high abundance (about 90%) of this strain type in main‐
stream Indian populations (Mukhopadhyay et al., 2000, Chattopadhyay et al., 2002, Datta et
al., 2003). This abundance is also remarkable, in light of the apparent absence of H. pylori-
associated gastrointestinal disease in these populations suggesting that H. pylori infections
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on an average are less virulent in these ethnic minorities than in mainstream Indians. Such
virulence might be due to subtle features of bacterial strains or intricacies of the human host
environment. For example, lesser virulence of the H. pylori strains themselves might be ascri‐
bed to subtle (e.g., point) mutations that affect levels of expression of virulence genes or the
potencies of their products, which do not, however, affect outcomes of diagnostic PCR tests
(Kersulyte et al., 1999, Philpott et al., 2002).
Antibiotics along with proton pump inhibitors (PPIs) known as ‘Triple therapy’ have been
used for H. pylori-infected patients by most physicians for high effectiveness and negligible
side effects However, long term ‘Triple therapy’ in H. pylori-infected patients may increase
atrophic gastritis (Kuipers et al., 1996). Omeprazole, the potent PPI used to treat reflux
esophagitis in H. pylori-infected patients, increase the proportion of atrophic gastritis com‐
pared to those patients receiving alternative treatments (Berstad et al., 1997, Eissele et al.,
1997, Klinkenberg-Knol et al., 2000). In addition, omeprazole initiates dysplasia in H. felis-
infected mice with over expressed gastrin (Takaishi et al., 2005). Therefore, the effect of long-
term PPI treatment over gastric microbiome needs further investigation. Antibiotic
treatments not only remove H. pylori but also other bacteria from gut microbiota some of
which may exacerbate disease condition. In theory, screening and treating patients for H. py‐
lori eradication by antibiotics would be economical; only if the probability of reducing gas‐
tric disorder is 30% or more (Parsonnet et al., 1996). Studies involving H. pylori eradication
by antibiotic treatment have shown reduced risk for tumor recurrence (Uemura et al., 1997),
or development of gastric cancer (Uemura et al., 2001, Wong et al., 2004) though little or no
significant improvement of gastric atrophy with H. pylori eradication has been reported
(Ruiz et al., 2001). In contrast, even increasing gastro-esophageal reflux is reported after H.
pylori eradication (Labenz et al., 1997), though other studies do not agree (Moayyedi et al.,
2001, Schwizer et al., 2001, Kuipers et al., 2004, Vaira et al., 2003). Therefore, antibiotic treat‐
ment to eradicate H. pylori in early infected patients may prevent the development of dis‐
ease; though it still remains unclear whether patients with advanced stages of the disease
can benefit from antibiotic intervention. In addition, long-term use of antibiotics kills the
beneficial bacteria thereby changing gut microbiota. The later would in turn affect host’s
metabolic and immunological functions, which may disrupt gut, liver and brain functions
(Nicholson et al., 2012). Moreover, the consequence in disease progression yet remains to be
explored in the context of modalities of H. pylori treatment. Therefore, gut microbiota influ‐
ence significantly on the host immune system and vice versa (Hooper et al., 2012).
Although, ‘Triple therapy’ is successful in individual cases, yet the recurrence of bacterial
infection especially in highly endemic countries makes vaccination as an alternative ap‐
proach to standard therapy. However, till date vaccination against H. pylori has not shown
much promise. Vaccination in various clinical trials of either preventive or therapeutic has
failed to generate successful immune response. Vaccination has been tested in many ways.
Firstly, intra-gastric immunization has been used in some studies to could efficiently stimu‐
late gastrointestinal immune response. However, this method requires large amount of anti‐
gen and adjuvant injection in gastric milieu which potentially raises other side-effects (Wu
et al., 2008). Secondly, intranasal immunization against H. pylori prove ineffective as it fails
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to stimulate immune system in stomach and intestine. Moreover, it increases the chance of
infection of olfactory bulb of brain (van Ginkel et al.). Finally, sublingual immunization
emerges as another approach, in which the vaccine or antigen do not enter the brain (Song et
al., 2008). Indeed, sublingual immunization against H. pylori strongly induces IFNγ, IL-17
along with increased expression of various integrins and chemokines facilitating the migra‐
tion of lymphocytes into stomach mucosa (Raghavan et al.).
Though large-scale research is going around the world in relation to H. pylori infection, yet
day by day the result is becoming exhaustive without a conclusive direction. The bacteria
colonize the gastric mucus layer and are continuously faced with harsh physiological condi‐
tions and a vigorous immune response. The need for adaptation to the extremely changing
micro-environment and to individual hosts (Van Vliet et al., 2002) is probably the cause of a
high degree of inter strain genetic variation observed in the H. pylori population worldwide.
(Blaser, 1994). So, identification of subpopulations at high risk of developing deleterious H-
pylori-related diseases remains a mainstream challenge for clinicians and basic researchers.
In relation to treatment, nothing absolute promising therapeutic has yet arrived in the mar‐
ket. So, the fundamental question that arises is should we treat infection or inflammation
with more priority? Since neither antibiotic treatment nor vaccine development have shown
much promise in recovery of infected patients. The approach of reducing inflammation may
arrest the development of gastric diseases. Epigenetic studies reveal that changes in the
DNA methylation pattern during infection are due to inflammation. One possibility entails
concurrent infection with particular parasites that may down regulate inflammatory re‐
sponses to infection, as has been documented in a mouse infection model (Martin et al.,
2000). Features of human host genotype might also determine resistance to pathogenic ef‐
fects of putatively virulent H. pylori strains (Ferrero and Fox, 2001, Ferrero and Jenks, 2001).
Also, inflammatory cytokines generates ROS within the cells and activate several MMPs that
further aggravate the inflammatory response leading towards disease progression. Finally,
while many studies have investigated the host genetic factors involved in gastric carcino‐
genesis (Hishida et al.), but there is an urgent need for extensive studies that will investigate
the genetic traits associated with the risk of gastric precancerous conditions. Particularly,
studies on polymorphism in the genes involved in host immunity against H. pylori infection
or the genes essential for the development/ differentiation of the gastric epithelial cells, are
the need of the time.
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